Neuroprotective Peptides: Cerebrolysin, Semax, Dihexa, and Pinealon

Neuroprotection — preventing neuronal death and preserving brain function in the face of injury, disease, or aging — is one of the most challenging frontiers in medicine. The brain's limited regenerative capacity means that protecting existing neurons is often more viable than replacing lost ones. Several peptides have shown genuine neuroprotective potential, but the evidence depth varies from multi-center clinical trials to single-laboratory preclinical reports.

Cerebrolysin: the most clinically studied neuroprotective peptide

Cerebrolysin is a standardized mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine brain tissue. It is not a single peptide but a defined peptide mixture — containing fragments that mimic the activity of endogenous neurotrophic factors including BDNF, NGF, CNTF, and GDNF.

Mechanism. Cerebrolysin provides multi-pathway neurotrophic support:

• Promotes neuronal survival by activating PI3K/Akt anti-apoptotic signaling
• Enhances synaptic plasticity through BDNF-like and CNTF-like signaling
• Supports dendritic branching and new synapse formation
• Reduces excitotoxic neuronal death from glutamate overactivation
• Promotes neurogenesis (new neuron formation) in the hippocampal dentate gyrus

This multi-target approach is biologically rational — neurodegeneration involves multiple simultaneous pathological processes, and a single-target intervention may be insufficient.

Stroke recovery. Cerebrolysin's strongest clinical data comes from stroke rehabilitation trials:

• The CASTA trial (Cerebrolysin and Recovery After Stroke, n=1,070) was a multicenter Phase 3 RCT in acute ischemic stroke. While the primary endpoint (ADAS-cog+ at 90 days) was not met in the overall population, pre-specified subgroup analyses showed significant improvement in patients with moderate-to-severe stroke.
• The E-COMPASS trial (n=70) showed that cerebrolysin combined with rehabilitation produced significantly greater motor recovery than rehabilitation alone after acute stroke.
• Multiple smaller RCTs have shown improvements in cognitive function, activities of daily living, and neurological recovery scores during post-stroke rehabilitation.

Alzheimer's disease. Several RCTs have evaluated cerebrolysin in mild-to-moderate Alzheimer's disease:

• The largest (n=280) showed significant ADAS-cog improvement at 24 weeks compared to placebo — with effect sizes comparable to approved cholinesterase inhibitors.
• A 6-month open-label follow-up showed sustained cognitive benefits.
• These trials are published in peer-reviewed journals but have not led to FDA approval. Cerebrolysin is registered in over 50 countries (predominantly in Europe, Asia, and Latin America) but not in the United States.

Protocol. 10-30 mL IV or IM daily for 10-20 day courses, repeated 2-4 times per year. The IV route is standard in clinical trials.

Honest assessment. Cerebrolysin has more clinical trial data than any other neuroprotective peptide. The evidence is real but has limitations — trials are moderate in size, some primary endpoints were missed while subgroup analyses were positive, and the compound has not achieved FDA approval. For post-stroke rehabilitation and early Alzheimer's disease, the evidence supports clinical use — which is why it is widely prescribed internationally. But definitive Phase 3 data meeting Western regulatory standards remains incomplete.

Semax: BDNF-mediated neuroprotection

Semax is a synthetic heptapeptide analog of ACTH(4-10) approved in Russia for cognitive disorders, stroke recovery, and optic nerve disease. Its neuroprotective mechanism centers on robust BDNF upregulation.

BDNF and neuroprotection. Brain-derived neurotrophic factor is the brain's primary endogenous neuroprotectant. It promotes neuronal survival through TrkB receptor activation, supports synaptic plasticity, and enhances neuronal repair. BDNF levels decline with age, depression, neurodegeneration, and chronic stress — making BDNF elevation a logical neuroprotective strategy.

What Semax does. Semax reliably increases BDNF expression in preclinical models and is associated with improved cognitive outcomes in Russian clinical trials for:

• Post-stroke cognitive recovery (improved attention, memory, and verbal function)
• Optic nerve atrophy (preservation of visual function)
• Transient ischemic attacks and cerebrovascular insufficiency

Neuroprotection-specific evidence. In animal models of cerebral ischemia, semax pretreatment or early administration:

• Reduced infarct volume by 25-40%
• Preserved blood-brain barrier integrity
• Reduced inflammatory cytokine expression in peri-infarct tissue
• Improved functional neurological outcomes

Limitations. The clinical trial data comes predominantly from Russian research institutions with smaller sample sizes and methodology that differs from Western regulatory standards. No multicenter Western replication has been conducted.

Protocol. 200-600 mcg intranasal daily, 2-4 week cycles.

Dihexa: extraordinary preclinical potency, zero clinical data

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an angiotensin IV analog that potentiates hepatocyte growth factor (HGF) signaling at the c-Met receptor. It is perhaps the most potent synaptogenic compound ever identified in preclinical research.

The preclinical data. Dihexa demonstrates synaptogenic activity at picomolar concentrations (10^-13 M) — orders of magnitude more potent than BDNF or any other known synaptogenic agent. In animal models:

• Reversed scopolamine-induced cognitive impairment
• Restored cognitive function in aged rats to levels comparable to young animals
• Promoted new synaptic connections and dendritic spine formation
• Crossed the blood-brain barrier after oral administration

Why the potency matters and does not matter. The extraordinary in vitro potency makes dihexa genuinely interesting from a mechanistic standpoint. However, in vitro potency does not predict clinical efficacy. The HGF/c-Met pathway is involved in cell proliferation and is dysregulated in multiple cancers — raising theoretical but unstudied long-term safety concerns.

The enormous gap. Zero human clinical trials. Zero human safety data. Zero dose-finding studies in humans. The distance between "reverses cognitive impairment in rats" and "safe and effective neuroprotectant in humans" includes hundreds of millions of dollars in clinical development and years of safety monitoring. Many compounds with spectacular preclinical profiles have failed completely in human trials.

Protocol (anecdotal). 10-20 mg oral daily. These doses come from extrapolation and self-experimentation reports, not clinical research.

Pinealon: the bioregulator approach

Pinealon (Glu-Asp-Arg) is a synthetic tripeptide bioregulator developed by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to a class of short peptides theorized to regulate gene expression in specific tissues — in pinealon's case, brain tissue.

The bioregulation concept. The Khavinson theory proposes that short peptides (2-4 amino acids) derived from specific tissues can regulate gene expression in those tissues by interacting directly with DNA. This is a non-mainstream concept in Western molecular biology, though the research group has published extensively in peer-reviewed journals.

What the evidence shows:

• Cell culture studies demonstrate neuroprotective effects against oxidative stress-induced neuronal death
• Animal studies show improved learning and memory in aged rats
• Small clinical studies in elderly patients report improved cognitive function and sleep quality
• Gene expression analyses suggest upregulation of antioxidant and anti-apoptotic pathways

Honest assessment. Pinealon's evidence base is concentrated within a single research group, the regulatory framework (cytogens/bioregulators) is not accepted by Western regulatory agencies, and independent replication is limited. The science is not implausible, but the evidence depth falls far short of cerebrolysin or even semax. Appropriate for those interested in the bioregulator paradigm, but not a first-line neuroprotective choice.

The neuroprotection evidence hierarchy

• Cerebrolysin: Multiple Phase 2/3 RCTs in stroke and Alzheimer's, registered in 50+ countries. Best-evidenced neuroprotective peptide globally. Confidence: moderate-to-high.
• Semax: Regulatory approval in Russia, clinical trial data for stroke recovery and optic nerve disease. Confidence: moderate.
• Pinealon: Small clinical studies, limited to one research group. Confidence: low.
• Dihexa: Preclinical only, extraordinary potency but zero human data. Confidence: very low for clinical use.

The foundation matters

Neuroprotection is not purely pharmacological. The most evidence-based neuroprotective interventions remain:

• Aerobic exercise: The strongest endogenous BDNF elevator, proven to increase hippocampal volume and reduce dementia risk
• Sleep optimization: Glymphatic clearance of neurotoxic proteins (amyloid-beta, tau) occurs during deep sleep
• Metabolic health: Insulin resistance impairs cerebral glucose utilization and accelerates neurodegeneration
• Cognitive engagement: Sustained cognitive challenge promotes synaptic density and cognitive reserve

Peptides add to this foundation. They do not replace it. Even cerebrolysin — the most clinically validated neuroprotective peptide — produces its best outcomes when combined with active rehabilitation, not as a standalone treatment. The brain responds to challenges and support simultaneously; providing only the support without the challenge leaves most of the neuroprotective potential on the table.